The HDEFONE project has developed two key methodologies that can propel further advances in neuroscience research, optical neuroimaging and the instrumentation required therefore.
First, methods have been developed that provide new perspectives for quantitative assessment of the data generated by an acquisition setup and prescribe protocols for further tuning the system design. These strategic methodologies can potentially serve as templates for the design and development of neuroimaging devices using quantitative model-backed methods to minimise the ethical impacts of in vivo tests for tuning and optimisation of the setup. In future, these methodologies could be further extended to develop individualised tuning targets to maximise data-fidelity.
Second, the new algorithms can provide improved assessments of neurovascular function. In tandem with the technological developments in hybrid diffuse optics instrumentation, these advances will benefit neuroscience research and neuro-critical care by providing large field of view imaging of brain function, to generate new scientific insights into the development, maturity and status of functional brain networks and guide individualised care decisions. Further research and investment in these technologies will open the possibility to image new demographics such as individuals under critical care, or infants in naturalistic environments.
In the short term, further refinement of the methodologies developed and thorough validations over a larger data set is essential to promote adoption of these methods. Continued research and demonstrations across different use-cases will pave the way to create a global appeal for these methods.
Furthermore, the activities of this project were aligned with another Horizon 2020 project, the TinyBrains (No. 101017113), which advanced the state of the art in instrumentation, probe design and scientific knowledge bringing new insights into assessment of brain function and injury in the peri-operative period. The project had significant potential for social impact, through indirect means via the scientific knowledge generated and direct means via the development of non-invasive cot-side neuromonitoring devices that can drive individualisation of critical care in CHD patients, paving the way for improvements in patient outcomes and hence their quality of life. The technologies developed therein, are on the path for further exploitation for scientific research as well as commercialisation.